Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers

Gynecologic Oncology

Volumn 95, Issue 1, 2004, Pages 139-144

  Hachisuga, Toru ^a   Saito, Toshiaki ^b   Kigawa, Junzo ^c   Ohwada, Michitaka ^d   Yamazawa, Koji ^e   Yasue, Akira ^f   Iwasaka, Tsuyoshi ^g   Sugiyama, Toru ^h   Kita, Tsunekazu ⁱ   Nagai, Nobutaka ^j  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

^d JICHI MEDICAL UNIVERSITY   (Japan)

^e CHIBA UNIVERSITY   (Japan)

^f FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g SAGA UNIVERSITY   (Japan)

^h IWATE MEDICAL UNIVERSITY   (Japan)

ⁱ NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^j HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Breast cancer; Clinicopathology; Endometrial cancer; Prognosis; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; POLYP; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RETROSPECTIVE STUDIES; TAMOXIFEN;

EID: 4644288425     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.07.019     Document Type: Article

References (25)

1. Early Breast Cancer Trialists' Collaborative Group, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 239 (1992) 1-15; 71-85.
2. T. Fornander, L.E. Rutqvist, B. Cedermark, U. Glas, A. Mattsson, and C. Silfversward Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers Lancet i 1989 117 120
3. B. Fisher, J.P. Costantino, C.K. Redmond, E.R. Fisher, D.L. Wickerham, and W.M. Cronin Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Projects (NSABP)B-14 J. Natl. Cancer Inst. 86 1994 527 537
4. F.E.V. Leeuwen, J. Benraadt, J.W.W. Coebergh, L.A.L.M. Kiemeney, C.H.F. Gimbrere, and R. Otter Risk of endometrial cancer after tamoxifen treatment of breast cancer Lancet 343 1994 448 452
5. L.E. Rutqvist, H. Johansson, T. Signomklao, U. Johansson, T. Fornander, and N. Wilking Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies J. Natl. Cancer Inst. 87 1995 645 651
6. H. Mignotte, C. Lasset, V. Bonadona, A. Lesur, E. Luporsi, and J.F. Rodier Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study Int. J. Cancer 76 1998 325 330
7. L. Bernstein, D. Deapen, J.R. Cerhan, S.M. Schwartz, J. Liff, and E.M. Maloney Tamoxifen therapy for breast cancer and endometrial cancer risk J. Natl. Cancer Inst. 91 1999 1654 1662
8. L. Bergman, M.L.R. Beelen, M.P.W. Gallee, H.H. Hollema, J. Benraadt, and F.E.V. Leeuwen Risk and prognosis of endometrial cancer after tamoxifen for breast cancer Lancet 356 2000 881 887
9. FIGO stages-1988 revision Gynecol. Oncol. 35 1989 125 126
10. T. Hachisuga, T. Kawarabayashi, T. Iwasaka, H. Sugimori, T. Kamura, and M. Tsuneyoshi The prognostic value of semiquantitative nuclear grading in endometrial carcinomas Gynecol. Oncol. 65 1997 115 120
11. R.E. Scully, T.A. Bonfiglio, R.J. Kurman, S.G. Silverberg, E.J. Wilkinson World Health Organization International histologic classification of tumours: histological typing of female genital tract tumours 2nd ed. 1994 Springer-Verlag Berlin 13 18
12. C.L. Creutzberg, W.L.J. van Putten, P.C.M. Koper, M.L.M. Lybeert, J.J. Jobsen, and C.C. Warlam-Rodenhuis Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial Lancet 355 2000 1404 1411
13. J.H. Farley, L.R. Nycum, M.J. Birrer, R.C. Park, and R.R. Taylor Age-specific survival of women with endometrioid adenocarcinoma of the uterus Gynecol. Oncol. 79 2000 86 89
14. K.M. Alektiar, E. Venkatraman, N. Abu-Rustum, and R.R. Barakat Is endometrial carcinoma intrinsically more aggressive in elderly patients? Cancer 98 2003 2368 2377
15. A.J. Mundt, S. Waggoner, D. Yamada, J. Rotmensch, and P.P. Connel Age as a prognostic factor for recurrence in patients with endometrial carcinoma Gynecol. Oncol. 79 2000 79 85
16. T. Hachisuga, T. Kaku, K. Fukuda, F. Eguchi, M. Emoto, and T. Kamura The grading of lymphovascular space invasion in endometrial carcinoma Cancer 86 1999 2090 2097
17. U. Magriples, F. Naftolin, P.E. Schwartz, and M.L. Carcangiu High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients J. Clin. Oncol. 11 1993 485 490
18. E.G. Silva, C.S. Tornos, and M.F. Mitchell Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen Int. J. Gynecol. Pathol. 13 1994 248 258
19. L. Deligdisch, T. Kalir, C.J. Cohen, M.D. Latour, G.L. Bouedec, and F.P. Llorca Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer Gynecol. Oncol. 78 2000 181 196
20. R.R. Barakat, G. Wong, J.P. Curtin, V. Vlamis, and W.J. Hoskins Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features Gynecol. Oncol. 55 1994 164 168
21. K.F. McGonigle, S.L. Shaw, S.A. Vasilev, T.O. Maryon, S. Roy, and J.F. Simpson Abnormalities detected on transvaginal ultrasonography in tamoxifen-treated postmenopausal breast cancer patients may represent endometrial cystic atrophy Am. J. Obstet. Gyncol. 178 1998 1145 1150
22. L.E. Hann, E.M. Gretz, A.M. Bath, and S.M. Francis Sonohysterography for evaluation of the endometrium in women treated with tamoxifen AJR 177 2001 337 342
23. L.B. Schwartz, L. Krey, R. Demopoulos, S.R. Goldstein, L.E. Nachtigall, and K. Mittal Alterations in steroid hormone receptors in the tamoxifen-treated endometrium Am. J. Obstet. Gynecol. 176 1997 129 137
24. W.G. Mccluggage, M. Abdulkader, J.H. Price, P. Kelehan, S. Hamilton, and J. Beattie Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases Int. J. Gynecol. Cancer 10 2000 280 284
25. X. Matias-Guiu, L. Catasus, E. Bussaglia, H. Lagarda, A. Garcia, and C. Pons Molecular pathology of endometrial hyperplasia and carcinoma Hum. Pathol. 32 2001 569 577